Literature DB >> 11171817

Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.

M Conio1, A J Cameron, Y Romero, C D Branch, C D Schleck, L J Burgart, A R Zinsmeister, L J Melton, G R Locke.   

Abstract

BACKGROUND: The incidence of oesophageal adenocarcinoma has increased greatly. Barrett's oesophagus is a known risk factor. AIMS: To identify changes in the incidence, prevalence, and outcome of Barrett's oesophagus in a defined population.
SUBJECTS: Residents of Olmsted County, Minnesota, with clinically diagnosed Barrett's oesophagus, or oesophageal or oesophagogastric junction adenocarcinoma.
METHODS: Cases were identified using the Rochester Epidemiology Project medical records linkage system. Records were reviewed with follow up to 1 January 1998.
RESULTS: The incidence of clinically diagnosed Barrett's oesophagus (>3 cm) increased 28-fold from 0.37/100 000 person years in 1965-69 to 10.5/100 000 in 1995-97. Of note, gastroscopic examinations increased 22-fold in this same time period. The prevalence of diagnosed Barrett's oesophagus increased from 22.6 (95% confidence interval (CI) 11.7-33.6) per 100 000 in 1987 to 82.6/100 000 in 1998. The prevalence of short segment Barrett's oesophagus (<3 cm) in 1998 was 33.4/ 100 000. Patients with Barrett's oesophagus had shorter than expected survival but only one patient with Barrett's oesophagus died from adenocarcinoma. Only four of 64 adenocarcinomas occurred in patients with previously known Barrett's oesophagus.
CONCLUSIONS: The incidence and prevalence of clinically diagnosed Barrett's oesophagus have increased in parallel with the increased use of endoscopy. We infer that the true population prevalence of Barrett's oesophagus has not changed greatly, although the incidence of oesophageal adenocarcinoma increased 10-fold. Many adenocarcinomas occurred in patients without a previous diagnosis of Barrett's oesophagus, suggesting that many people with this condition remain undiagnosed in the community.

Entities:  

Mesh:

Year:  2001        PMID: 11171817      PMCID: PMC1760138          DOI: 10.1136/gut.48.3.304

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

1.  Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings.

Authors:  A J Cameron; A R Zinsmeister; D J Ballard; J A Carney
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

2.  Adenocarcinomas arising in tongues or short segments of Barrett's esophagus.

Authors:  T G Schnell; S J Sontag; G Chejfec
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

3.  Conservative operations for peptic esophagitis with stenosis in columnar-lined lower esophagus.

Authors:  A P Naef; M Savary
Journal:  Ann Thorac Surg       Date:  1972-06       Impact factor: 4.330

Review 4.  Barrett's esophagus.

Authors:  S J Spechler; R K Goyal
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

5.  Barrett's esophagus in patients with symptomatic reflux esophagitis.

Authors:  N S Mann; M F Tsai; P K Nair
Journal:  Am J Gastroenterol       Date:  1989-12       Impact factor: 10.864

6.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.

Authors:  A J Cameron; H A Carpenter
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

7.  Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.

Authors:  C Winters; T J Spurling; S J Chobanian; D J Curtis; R L Esposito; J F Hacker; D A Johnson; D F Cruess; J D Cotelingam; M S Gurney
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

8.  Barrett's esophagus. Prevalence and incidence of adenocarcinoma.

Authors:  W A Williamson; F H Ellis; S P Gibb; D M Shahian; H T Aretz; G J Heatley; E Watkins
Journal:  Arch Intern Med       Date:  1991-11

9.  Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction.

Authors:  S R Hamilton; R R Smith; J L Cameron
Journal:  Hum Pathol       Date:  1988-08       Impact factor: 3.466

10.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia.

Authors:  W J Blot; S S Devesa; R W Kneller; J F Fraumeni
Journal:  JAMA       Date:  1991-03-13       Impact factor: 56.272

View more
  58 in total

1.  Barrett's oesophagus: epidemiology comes up with a surprise.

Authors:  R C Heading
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

2.  Risk of adenocarcinoma in Barrett's oesophagus: population based study.

Authors:  Liam Murray; Peter Watson; Brian Johnston; James Sloan; Inder Mohan Lal Mainie; Anna Gavin
Journal:  BMJ       Date:  2003-09-06

3.  Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.

Authors:  S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

4.  Familial association in barrett esophagus.

Authors:  Yvonne Romero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-05

5.  Are We Making Progress in Preventing Barrett's-Related Esophageal Cancer?

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

6.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

7.  Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.

Authors:  Aaron P Thrift; Lesley A Anderson; Liam J Murray; Michael B Cook; Nicholas J Shaheen; Joel H Rubenstein; Hashem B El-Serag; Thomas L Vaughan; Jennifer L Schneider; David C Whiteman; Douglas A Corley
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

Review 8.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 9.  The changing face of esophageal malignancy.

Authors:  Timothy R Koch
Journal:  Curr Gastroenterol Rep       Date:  2003-06

10.  Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.

Authors:  Judy S Wang; Andrea Varro; Charles J Lightdale; Nantaporn Lertkowit; Kristen N Slack; Michael L Fingerhood; Wei Yann Tsai; Timothy C Wang; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2009-11-10       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.